Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
31 mai 2023 16h50 HE
|
Cellectis Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano
30 mai 2023 06h12 HE
|
Tessa Therapeutics Ltd
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Skin Graft Market (Product, Graft Thickness) - Reach $1.67Bn by 2028 at 7% CAGR with Autologous Segment Driving Growth During 2021–2028 | The Insight Partners
18 mai 2023 10h54 HE
|
The Insight Partners
Pune, India., May 18, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research report on "Skin Graft Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Graft...
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
17 mai 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
12 mai 2023 01h30 HE
|
Cellectis Inc.
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
11 mai 2023 10h20 HE
|
Cellectis Inc.
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
10 mai 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
04 mai 2023 16h30 HE
|
Cellectis Inc.
First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s alemtuzumabCellectis...
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 16h35 HE
|
Cellectis Inc.
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
24 avr. 2023 16h30 HE
|
Cellectis Inc.
Cellectis demonstrated that the addition of alemtuzumab to the lymphodepletion regimen was associated with prolonged lymphodepletion and significantly higher cell expansion and clinical activity NEW...